FDA Greenlights Gene Therapy, Because Patience Isn’t a Drug
In a plot twist worthy of a soap opera, the FDA announced it’s 'clearing the way' for Sarepta Therapeutics to resume shipments of their gene therapy for Duchenne muscular dystrophy to some patients. Yes, just some, because apparently miracles come with fine print. The FDA’s official line? They’re 'clearing the way,' which sounds a bit like popping open a space in traffic, except this lane could save lives. Gene therapy shipments resumed, but if you were hoping for a full-on party, well, it’s more of a dignified nod: progress served with a side of bureaucratic seasoning.
Share the Story
(1 of 3)FDA finally said 'go' for gene therapy shipments, or as they put it, 'clearing the way.' Someone tell my delivery app to work on that kind of speed. #MiracleMiles
Oh look, FDA is 'clearing the way' for some shipments like it's GPS rerouting around traffic jams. Your gene therapy might arrive sometime between now and the heat death of the universe.
Resuming gene therapy shipments to some patients is like giving only half your friends passes to the Electric Daisy Carnival—exclusive, selective, and sure to cause FOMO.
Source: Statnews | Published: 7/28/2025 | Author: Adam Feuerstein
More Articles in Health
Army Launches 9-1-1 Hotline Because Soldiers Really Love Calling IT
Microsoft Finally Lets Windows 11 Fans Stop Pretending to Use ViVeTool
Epstein Survivors Declare 'Done' While Melania Passes the Buck Faster Than a Baton
Telehealth Startup Outsources Doctors to AI and Angolan Phone Lines
Widow Turns Frozen Sperm Time Capsule Into Baby After 10-Year Hiatus
OpenAI CEO Temporarily Downgrades from AI Overlord to Human POTS Patient
Woman Quits Job at 38 to Audit Diaper Changing as Full-Time Gig
Utah Lets Robot Shrink Prescribe Meds, Because What Could Go Wrong?
